Protease-activation of fc-masked therapeutic antibodies to alleviate off-tumor cytotoxicity

HIGHLIGHTS

• who: Adrian Elter from the Tel Aviv University, Israel Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany have published the research work: Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity, in the Journal: (JOURNAL)
• what: Generation of FcgR-Blocking Anti-Isotypic Masking Units For the generation of a suitable masking unit, which specifically targets the FcgR-binding_site of antibodies, the authors focused on implementation of anti-isotypic (anti-IgG1) single-chain variable fragments (scFvs).

SUMMARY

In the last decades monoclonal_antibodies (mAbs) became powerful and promising . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.